Abstract Epigenetic abnormalities including abnormal histone methyltransferase activity contribute to breast cancer pathogenesis. An example is over expression of the polycomb repressive complex (PRC) 2 member enhancer of zeste homolog 2 (EZH2) which is linked to epigenetic silencing and poor prognosis. Recent evidence shows that S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors (AHI) such as 3-deazaneplanocin A (DZNep) modulate chromatin through indirect inhibition of histone methyltransferases including EZH2. We investigated the biological effects of AdoHcy hydrolase inhibition using DZNep and its structural analogues 3-deazaadenosine (DZA) and neplanocin A (Nep A) in breast cancer cells. EZH2 protein expression was decreased and dose dependent growth inhibition occurred with variable potencies in MCF7, MDA-MB-231 and SKBr3 breast cancer cells. Cellular proliferation was inhibited through G 2 /M cell cycle arrest and apoptosis. In addition breast cancer cells accumulated cytoplasmic lipid droplets in response to AdoHcy hydrolase inhibition consistent with a differentiating effect. Each analogue induced a similar pattern of biological activity against breast cancer cells but with differences in potency (DZA [ DZNep [ Nep A). Co-administration with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) induced synergistic inhibition of breast cancer cell proliferation. Furthermore, the relatively AHI resistant human epidermal growth factor receptor 2 (HER2) positive cell line SKBr3 underwent synergistic growth inhibition in response to co-treatment with the HER2 directed therapeutic antibody trastuzumab. In conclusion, AHI induce growth inhibition, cell cycle arrest, apoptosis and differentiation in breast cancer cells and synergise with HDAC and HER2 inhibition. Targeting histone methyltransferase activity might be of therapeutic value in breast cancer.
Introduction
In addition to abnormalities of DNA sequence, epigenetic changes are also recognised to underpin breast cancer development. Such abnormalities are attractive for therapeutic intervention in that, unlike DNA sequence changes, they are potentially open to direct modulation through inhibition of enzymatic mediators [1, 2] . Abnormal epigenetic marks in breast cancer are described at the level of DNA methylation and post-translational modifications to histones. Histone acetylation generally functions as a transcriptionally activating mark whilst DNA methylation at gene promoters produces repression. In contrast, histone methylation marks may be either repressive or activating dependent on the relevant lysine/arginine methylation site within the histone tail [1] . In addition to DNA methylation and histone acetylation, there is increasing evidence to implicate histone methylation as a potential therapeutic target for cancer. The main mediator of histone methylation studied to date in breast cancer is EZH2, a member of PRC2 which also includes embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12). EZH2 has a role in regulation of transcriptional regulation and chromatin state. PRC2 induces silencing initiation whilst a further complex, PRC1, with more variable composition including BMI1 and RING1b, allows for gene silencing maintenance. EZH2 is a histone methyltransferase which induces transcriptionally repressive trimethylation marks at histone H3 lysine 27 (H3K27me3) [3, 4] . Histone lysine methyltransferases such as EZH2 require methyl group donation from the cofactor S-adenosyl-L-methionine (AdoMet). EED and SUZ12 are required in complex for full functional activity. In addition, EZH2 induces transcriptional effects distinct from its histone methylation and methyltransferase activity, for example transcriptionally repressive or activating effects mediated through oestrogen and Wnt signalling pathways [5] [6] [7] [8] . EZH2/PRC2 activity occurs in concert with other transcriptionally repressive epigenetic processes. Thus, histone methyltransferase activity of EZH2 is potentiated by the recruitment of HDAC activity through interaction with EED [9] . Furthermore, DNA methyltransferase binding to EZH2 repressed genes depends on the presence and activity of EZH2 which is required for DNA methylation of EZH2 target promoters [10] .
EZH2 is over-expressed in breast cancer compared with normal breast epithelia and expression is associated with invasiveness, increased proliferation, markers of an aggressive phenotype (basal or HER2 positive) and reduced survival outcomes [11] [12] [13] [14] [15] . Overexpression of EZH2 in immortalized mammary epithelial cell lines promotes anchorage independent growth and cell invasion and EZH2 over-expressing cells are tumorigenic when injected into mammary fat pads of nude mice [14, 16] . Furthermore, EZH2 is required for embryonic stem cell survival and deletion is embryonic lethal [17] . EZH2 knockdown in oestrogen receptor negative cell line models decreased proliferation, inhibited G 2 /M cell cycle transition and suppressed xenograft growth [18] . Therefore, evidence for the role of EZH2 in breast cancer indicates a potential therapeutic target for the manipulation of epigenetic processes in breast cancer at the level of histone methylation. Furthermore, abnormal expression has been shown in breast cancer for other histone methyltransferases (e.g. NSD3 amplification, SMYD3 over expression and PRMT1 depletion) along with over expression of the histone demethylase JARID1B [19] . These are less well researched regarding relevance to breast cancer pathogenesis or potential therapeutic targets.
Recent evidence indicates that the carbocyclic adenosine analogue DZNep has anti-tumour activity which stems, at least in part, from PRC2 inhibition through decreased expression and activity of EZH2. DZNep inhibits AdoHcy hydrolase, preventing hydrolysis of AdoHcy to homocysteine and methionine. Subsequent cellular accumulation of AdoHcy results in upstream inhibition of AdoMet metabolism (to AdoHcy). AdoMet metabolism represents a key cellular mechanism for methyl group donation for a variety of dependant metabolic processes which are, therefore, disrupted, including production of methyltransferases such as EZH2.
DZNep and other AHI analogues have been previously investigated as potential anti viral agents [20] . In an initial report describing anticancer effects, DZNep induced depletion of EZH2, EED and SUZ12, and reversal of repressive H3K27me3 and H4K20me3 marks along with apoptosis in breast cancer (MCF7) and colorectal cancer cell line models. DZNep induced re-expression of a gene set with partial overlap to those re-expressed by siRNA depletion of PRC2 components. Precise mechanisms of EZH2 depletion by DZNep remain unclear but appear to be in part a function of proteasomal degradation and linked to dependency of PRC2 members on each other for stability and function [21] [22] [23] . Subsequent work has shown DZNep is in fact likely to have broader inhibitory effect on methyltransferases beyond EZH2. Indeed, removal of both repressive (H3K27me3, H4K20me3) and activating (H3K4me3) but not all (H3K9me3, H3K36me3) histone methylation marks was demonstrated [24] . Thus, DZNep likely acts as a broad methyltransferase inhibitor with effects on both inhibitory and activating histone methylation marks that might allow resetting of the epigenetic 'ground state' [24] . Differences have been seen in the patterns of activating trimethylation marks at H3K4 in response to DZNep which were depleted in HT29, SW480 (colorectal) and MCF7 (breast) cancer cell lines but increased in OCI-AML3 and HCL-60 (acute myeloid leukaemia, AML) cells [21, [23] [24] [25] . Thus, effects by this agent may be cancer and/or context specific.
Here, we describe biological anti-cancer effects of DZNep in multiple breast cancer cell lines and extend findings to other AHI structural analogues for the first time. In addition, we have investigated interactions seen with potentially complementary epigenetic and targeted therapeutic approaches for breast cancer. 
Methods

Cell lines and reagents
Immunoblotting
Cells were plated at 1.5 9 10 5 per 35 mm well. After 24 h, cells were treated by replacement of culture medium supplemented with the indicated compound or equivalent concentration of DMSO solvent. Samples were harvested as previously described for histone modifications [26] and for other proteins using detergent lysates [27] . Antibodies used were mouse monoclonal anti-EZH2 (3147) from New England BioLabs (UK) Ltd (Hitchin, UK), mouse monoclonal anti-HSC70 (sc-7298) and rabbit polyclonal anti-HER2 (sc-284) from Santa Cruz Biotechnology (Santa Cruz, CA) and rabbit polyclonal anti-H3K27me3 and rabbit polyclonal anti-acetylated histone H4 at lysine 8 (acH4K8) from Millipore (U.K.) Limited (Watford, UK). HSC70 expression was used as a protein loading control. Results are representative from a minimum of two separate experiments.
Cell proliferation assays
Cells (1000/well in a 96 well plate) were incubated for 6 days in various concentrations of compound or solvent control, prior to cell number analysis using MTS reagent (Promega, Southampton, UK) according to the manufacturer's instructions. 5 ll MTS reagent was added per well containing 100 ll of culture medium for 1.5 h prior to colorimetric analysis on a Varioskan Flash spectral plate reader (Thermo Scientific, Basingstoke, UK). Each data point was derived from triplicate determinations and results are expressed as mean values as percentage MTS conversion with respect to samples exposed to DMSO solvent alone. (DMSO did not alter MTS conversion compared to untreated cells in any experiment, data not shown). IC 50 values were derived following non linear regression using GraphPad Prism software (GraphPad Software, La Jolla, CA) and are presented as mean values ± SEM from a minimum of three separate experiments in each cell line for each compound. Synergism in cell proliferation assays, as a result of combination exposure to compounds, was assessed using fractional effect analyses using CalcuSyn software (version 2.0, Biosoft, Cambridge, UK) according to the manufacturer's instructions. This software produces a combination index (CI) value where a value of less than 1.0 indicates a synergistic interaction [28] .
Cell cycle analysis
Cells were plated at 1.5 9 10 5 per 35 mm well. At 24 h, cells were treated by replacement of culture medium supplemented with the relevant AHI compound or equivalent concentration of DMSO solvent for the indicated durations. Cells were harvested and stained with propidium iodide (PI) for analysis of cell cycle phase and sub-G 1 fraction content using flow cytometry as previously described [29] . Data were analysed as the percentage of cells in the indicated cell cycle phase of total cells in cell cycle and for analyses of cells in the sub-G 0 fraction as the percentage of total cells. Presented data are a representative experiment from a minimum of two separate experiments in each indicated cell line. All experiments were performed with triplicate determinations for each data point.
Analysis of apoptosis
Cells were plated at 1.5 9 10 5 per 35 mm well. At 24 h, cells were treated by replacement of culture medium supplemented with the indicated compound or equivalent concentration of DMSO. Cells were harvested after the durations indicated and flow cytometry was undertaken as previously described [29] . Cells were stained by resuspending in 500 ll of binding buffer containing 2.5 ll of annexin V-FITC, 1.25 ll of PI or both per sample. Presented data are a representative experiment from a minimum of two separate experiments in each indicated cell line. All experiments were performed with triplicate determinations for each data point. Data are presented as the percentage of total cells that are either live (unstained), early apoptotic (annexin V positive) or late apoptotic (annexin V/PI positive). Differentiation analysis 1.5 9 10 5 cells per 35 mm well were plated on pre-sterilised microscope slides. After 24 h cells were treated with DZNep. Nile red staining for analysis of differentiation (of cytoplasmic lipid droplet accumulation) according to the methods of Greenspan et al. [30] , was carried out as previously described [29] . All data are representative from a minimum of two separate experiments. Presented data are a representative experiment from a minimum of two separate experiments in each indicated cell line. Lipid droplet quantification was undertaken in three separate representative microscope fields and a mean value per field of view ± SEM was determined.
Statistics
Determinations of statistically different mean values were performed using Students t-test.
Results
AHI analogues inhibit cell proliferation in breast cancer cells
Although previous reports show that DZNep can induce apoptosis in breast and other cancer cell lines [23] , the structural analogues Nep A and DZA remain untested regarding their anticancer activity. We compared each in cell proliferation assays, revealing significant and consistent differences in potencies with respect to growth inhibition in each of three breast cancer cell lines (Fig. 1b, c, d, (Fig. 1f) .
AdoHcy hydrolase inhibition induces G 2 /M cell cycle arrest and apoptosis of breast cancer cell lines Having shown that AHI analogues inhibit proliferation of breast cancer cells, we investigated if this was due to cell cycle arrest and/or cell death. Time course experiments to determine cell cycle effects of DZNep were performed at a dose of 10 lM as this was found to produce robust inhibition of cell proliferation ( Fig. 2; Supplementary Table  S1 ). DZNep induced cell cycle arrest and significant increase in the G 2 /M cell component after 72 h in MCF7 and MDA-MB-231 cells (Fig. 2b, c; Supplementary Table  S1 ). SKBr3 cells remained relatively resistant to DZNep until 144 h undergoing a more modest but statistically significant G 2 /M arrest (Fig. 3d, Supplementary Table S1 ). DZNep also induced a significant increase in the sub-G 0 cell component (indicative of cell death) after 144 h in each cell line (Fig. 2e, Supplementary Table S1 ). We also tested the effects of DZA on cell cycle progression and again found G 2 /M cell cycle arrest and cell death after 72 h in MCF7 cells (Fig. 2f, g, Supplementary Table S2 ).
Experiments to determine if cell death was occurring through induction of apoptosis revealed a significant increase in annexin V and annexin V/PI positive cells after 144 h exposure to 10 lM DZNep in all three breast cancer cell lines (Fig. 3) indicating induction of apoptosis in response to AdoHcy hydrolase inhibition.
AdoHcy hydrolase inhibition induces cytoplasmic lipid accumulation in breast cancer cells
After 72 h exposure to DZNep, MCF7 and MDA-MB-231 cells underwent morphological changes, increasing in size with a reduced nuclear to cytoplasmic ratio and lacking the regular uniform order of untreated cells. Changes in SKBr3 cells were less marked (Fig. 4a) . Accumulation of cytoplasmic lipid droplets is validated as an experimental marker of cellular differentiation in breast cancer cells using methods described by Greenspan et al. [26, [29] [30] [31] . We, therefore, undertook Nile red staining of cytoplasmic lipid droplets following DZNep exposure. This revealed significantly increased droplet numbers in all three cell lines although SKBr3 cells have higher background staining and a less marked increase compared to untreated cells (Fig. 4b, c) . These results are consistent with a differentiation response to AdoHcy inhibition in breast cancer cells.
Combination AdoHcy hydrolase/HDAC inhibition has synergistic anti-breast cancer effects Combination epigenetic approaches are being investigated clinically and previous reports indicate synergistic interactions between HDAC inhibition and DZNep in AML and colorectal cancer models [22, 25, 32] . We, therefore, investigated for interactions between either DZNep or DZA and the pan zinc dependant (class I, II and IV) HDAC inhibitor TSA in breast cancer cell lines in growth inhibition assays. We found synergistic interaction with respect to growth inhibition between DZNep and TSA in MCF7 and MDA-MB-231 cells (Fig. 5a ). For example, at doses of 100 and 25 nM, respectively, the individual drugs inhibited growth by less than 10% in MCF7 cells, compared to over 40% when the drugs are combined. In MCF7 and MDA-MB-231, cells' evidence for a synergistic interaction was supported by detection of a CI value of less than 1.0. In contrast, DZNep and TSA were found to be additive (CI & 1) rather than synergistic in SKBr3 cells. EZH2 expression and acH4K8 were assessed in cell lines treated with DZNep, TSA or both in all three cell lines (Fig. 5b) . In each, EZH2 depletion and H4K8 hyperacetylation was detected in response to each agent individually which was greater with dual administration.
Combination growth inhibition assays were further explored using 25 nM DZA and 25 nM TSA (Fig. 5c ). Significantly increased growth inhibition was observed in all cell lines with the combination treatment compared to either agent alone. Evidence for a synergistic interaction was supported by a CI value \1.0 for each cell line. Immunoblot analysis demonstrated depletion of both EZH2 expression and H3K27 trimethylation to be enhanced in DZA and TSA dual treated cells (Fig. 5d) .
Combined AdoHcy hydrolase/HER2 inhibition synergizes in HER2 over-expressing breast cancer cells Our experiments found AHIs to be less potent against SKBr3 cells which are a model for HER2 over-expressing breast cancer. We, therefore, hypothesized that combination therapy with the HER2 directed therapeutic monocolonal antibody trastuzumab might 'unlock' sensitivity to inhibitors of AdoHcy hydrolase. Combination growth inhibition assays were performed for AdoHcy hydrolase inhibition and trastuzumab in SKBr3 cells (Fig. 6a) . More marked growth inhibition was observed with the combination treatment supported by a CI of 0.05 indicating strong synergism. Immunoblot analysis revealed a decrease in HER2 expression after either DZA or trastuzumab which was augmented by combination treatment (Fig. 6b) .
Discussion
Recent data have shown EZH2 depletion and modification of histone methylation status by DZNep in MCF7 breast cancer cells [23, 24] . We sought to characterise the biological effects of this and other AHI compounds in model systems for this disease. Our results confirm the ability of DZNep to reduce expression of EZH2 in MCF7 cells but also now other breast cancer cell lines and to inhibit cell proliferation with nanomolar potency. Importantly, this anti-proliferative effect was not seen in two non-malignant cell line models. Thus, analogous to HDAC inhibition, AdoHcy hydrolase inhibition may provide an opportunity to target a therapeutic window between malignant and nonmalignant cells by exploiting differing epigenetic profiles. However, the difference in potency ratio between malignant and non-malignant models is markedly greater for AHIs than for HDAC inhibitors where ratios of 4-30-fold in potency are described [26, 34] . Our work, therefore, provides a rationale to target histone methylation dynamics in breast cancer.
For the first time, we have also demonstrated anti-breast cancer effects for other AHIs using the DZNep structural analogues DZA and Nep A. Over 30 carbocyclic and acyclic adenosine analogue AHIs have been investigated for antiviral activity since the 1980s. Most exhibit broad antiviral activity which correlates to in vitro potency as AdoHcy hydrolase inhibitors [20] . As the mechanism of activity is through secondary inhibition of methyl donors from AdoMet, it is reasonable to assume that AdoMet dependant methyltransferase inhibition, and thus anticancer activity, represents a class effect. We investigated differences (DZA [ DZNep [ Nep A) in anti-breast cancer cell potency occurred amongst the compounds. In contrast, from the antiviral literature, differing relative antiviral potencies (inhibition of cytopathogenicity in primary rabbit kidney cells against vaccinia or vesicular stomatitis viruses) were seen for these compounds (DZNep & NepA [ DZA) [20] . Factors underpinning potency differences as anti-cancer agents such as cellular uptake, intra cellular drug metabolism, AdoHcy hydrolase affinity, target specificity and drug efflux remain to be determined. Further investigation of the anti-cancer activity of this group of compounds is warranted and raises opportunities to begin to dissect structure/function relationships. Beyond this agent class, specific inhibitors of EZH2 and other methyltransferase enzymes would be of great interest. This would allow assessment of specificity of action on anticancer activity in comparative studies to AHIs which appear likely to be indirect broad methyltransferase inhibitors [24] . As with HDAC inhibition, it remains unclear whether target selectivity (e.g. for EZH2) will be valuable when developing a therapeutic approach based around histone methyltransferase activity. Having demonstrated potent anti-breast cancer effects of AHIs, we sought to describe the biological processes underpinning this. We have shown that both DZNep and DZA have multifactorial anticancer effects including induction of G 2 /M cell cycle arrest, apoptosis and differentiation. Thus, inhibition of AdoMet dependent methyltransferases by AHIs to reset epigenetic abnormalities in breast cancer mirrors biological effects produced by HDAC inhibition [26, 33] . We found such effects generally required 72-144 h to become apparent at concentrations around the IC 50 value for growth inhibition in contrast to HDAC inhibition which in our experience is more rapid in its biological action (typically 24-72 h) [26] . This may have implications if such compounds were developed towards clinical applications in terms of duration of exposure required for biological effect. This prolonged delay to biological outcome is also notable in light of recent data indicating that the epigenetic 'ground state' may rapidly reset (at least at the level of gene expression) following removal of DZNep [24] .
We have also demonstrated synergistic interactions between AHIs and HDAC inhibition mirroring recent description of similar interactions in acute myeloid leukaemia and colorectal cancer models [22, 25] . Clinical evidence for efficacy of HDAC inhibition as a single agent approach in breast cancer has been modest to date and we and others have argued that HDAC inhibition will require a combination therapeutic strategy for optimal outcomes [32, 34, 35] . Our results are consistent with a model whereby optimal anti-breast cancer effect is dependent on a more profound reset of underlying epigenetic abnormalities requiring both HDAC and histone methyltransferase inhibition. PRC2 recruitment of HDACs by EED to augment transcriptional repression might potentially underpin the mechanism by which such synergy occurs [9] . Such combination strategies should, therefore, be investigated further for this disease as well as combinations with DNA methyltransferase inhibition in view of the recruitment of DNA methyltransferase activity to H3K27me3 repressive marks by EZH2 [10] . In addition, we have demonstrated synergistic interaction between AHIs and trastuzumab in a HER2 overexpressing breast cancer model. This was accompanied by a reduction in HER2 protein expression which was maximised by co-administration. Mechanisms for HER2 depletion remain to be elucidated but might include effects on transcription through chromatin remodelling or indirectly for example by interacting with chaperone (e.g. HSP90) function as is seen with HDAC inhibition [36] . Therapeutic targeting of histone methylation status in combination with established anti HER2-targeted therapies may, therefore, be of value in breast cancer subtypes dependant on this pathway. The mechanistic interaction between these two therapeutic approaches warrants further investigation.
In conclusion, we have demonstrated that the anti-breast cancer effects of AdoHcy hydrolase inhibition are underpinned by G 2 /M cell cycle arrest, apoptosis and cellular differentiation and that these are class effects for AHI analogues. Furthermore, AHIs produce synergistic interactions with HDAC inhibition and HER2-targeted therapy in breast cancer models. Our findings provide a basis for the development of therapeutic strategies to target histone methylation profiles in breast cancer.
